Elisabeth Rexen Ulven

List of Publications by Year
in descending order

34 papers	1,744 citations	304743 22 h-index	377865 34 g-index
37 all docs	37 docs citations	37 times ranked	1946 citing authors

#	Article	IF	Citations
1	Chemogenetics defines a short-chain fatty acid receptor gutâ€"brain axis. ELife, 2022, 11, .	6.0	21
2	Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans. Clinical Nutrition, 2021, 40, 2169-2179.	5.0	5
3	Structureâ€Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2. ChemMedChem, 2021, 16, 3326-3341.	3.2	2
4	FFA2-, but not FFA3-agonists inhibit GSIS of human pseudoislets: a comparative study with mouse islets and rat INS-1E cells. Scientific Reports, 2020, 10, 16497.	3.3	17
5	Structureâ€"Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators. Journal of Medicinal Chemistry, 2020, 63, 3577-3595.	6.4	8
6	Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2018, 61, 9534-9550.	6.4	29
7	Structure-Activity Investigations and Optimisations of Non-metabolite Agonists for the Succinate Receptor 1. Scientific Reports, 2018, 8, 10010.	3.3	11
8	Dihydropyridine Fluorophores Allow for Specific Detection of Human Antibodies in Serum. ACS Omega, 2018, 3, 7580-7586.	3.5	6
9	Polyunsaturated fatty acid receptors, GPR40 and GPR120, are expressed in the hypothalamus and control energy homeostasis and inflammation. Journal of Neuroinflammation, 2017, 14, 91.	7.2	104
10	Development and Characterization of a Fluorescent Tracer for the Free Fatty Acid Receptor 2 (FFA2/GPR43). Journal of Medicinal Chemistry, 2017, 60, 5638-5645.	6.4	32
11	Receptor structure-based discovery of non-metabolite agonists for the succinate receptor GPR91. Molecular Metabolism, 2017, 6, 1585-1596.	6.5	40
12	Structureâ€based discovery of novel US28 small molecule ligands with different modes of action. Chemical Biology and Drug Design, 2017, 89, 289-296.	3.2	10
13	Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer. Journal of Medicinal Chemistry, 2016, 59, 4849-4858.	6.4	40
14	Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity. Journal of Medicinal Chemistry, 2016, 59, 8868-8878.	6.4	81
15	Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy. Journal of Medicinal Chemistry, 2016, 59, 2841-2846.	6.4	20
16	A protocol for amide bond formation with electron deficient amines and sterically hindered substrates. Organic and Biomolecular Chemistry, 2016, 14, 430-433.	2.8	72
17	Dietary Fatty Acids and Their Potential for Controlling Metabolic Diseases Through Activation of FFA4/GPR120. Annual Review of Nutrition, 2015, 35, 239-263.	10.1	87
18	Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. British Journal of Nutrition, 2015, 113, 1677-1688.	2.3	93

#	Article	IF	Citations
19	Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor Ligands. Molecular Pharmacology, 2014, 86, 200-210.	2.3	58
20	In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 1021-1030.	3.0	12
21	Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability. Journal of Medicinal Chemistry, 2013, 56, 982-992.	6.4	52
22	Defining the Molecular Basis for the First Potent and Selective Orthosteric Agonists of the FFA2 Free Fatty Acid Receptor. Journal of Biological Chemistry, 2013, 288, 17296-17312.	3.4	99
23	Mucus can change the permeation rank order of drug candidates. International Journal of Pharmaceutics, 2013, 452, 276-282.	5.2	7
24	Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Medicinal Chemistry Letters, 2013, 4, 441-445.	2.8	58
25	Reevaluation of Fatty Acid Receptor 1 as a Drug Target for the Stimulation of Insulin Secretion in Humans. Diabetes, 2013, 62, 2106-2111.	0.6	64
26	The Pharmacology of TUG-891, a Potent and Selective Agonist of the Free Fatty Acid Receptor 4 (FFA4/GPR120), Demonstrates Both Potential Opportunity and Possible Challenges to Therapeutic Agonism. Molecular Pharmacology, 2013, 84, 710-725.	2.3	172
27	Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB Journal, 2012, 26, 4951-4965.	0.5	75
28	Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Mesylpropoxy Appendage Lowers Lipophilicity and Improves ADME Properties. Journal of Medicinal Chemistry, 2012, 55, 6624-6628.	6.4	50
29	Identification of a Potent and Selective Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist with Favorable Physicochemical and in Vitro ADME Properties. Journal of Medicinal Chemistry, 2011, 54, 6691-6703.	6.4	65
30	Conjugated Linoleic Acids Mediate Insulin Release through Islet G Protein-coupled Receptor FFA1/GPR40. Journal of Biological Chemistry, 2011, 286, 11890-11894.	3.4	51
31	Selective Orthosteric Free Fatty Acid Receptor 2 (FFA2) Agonists. Journal of Biological Chemistry, 2011, 286, 10628-10640.	3.4	101
32	A Rapid and Efficient Sonogashira Protocol and Improved Synthesis of Free Fatty Acid 1 (FFA1) Receptor Agonists. Journal of Organic Chemistry, 2010, 75, 1301-1304.	3.2	16
33	Structureâˆ’Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469. ACS Medicinal Chemistry Letters, 2010, 1, 345-349.	2.8	56
34	Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA₁/GPR40), a Potential Target for the Treatment of Type II Diabetes. Journal of Medicinal Chemistry, 2008, 51, 7061-7064.	6.4	127